Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

DATROWAY

DATOPOTAMAB DERUXTECAN-DLNK

Standard Dose
100MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview DATROWAY is listed in Drugs@FDA under application 761464 (BLA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient DATOPOTAMAB DERUXTECAN-DLNK Form and strength INJECTABLE;INJECTION - 100MG Sponsor DAIICHI SANKYO INC Submission history Latest submission status date: 2025-06-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview DATROWAY is listed in Drugs@FDA under application 761464 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient DATOPOTAMAB DERUXTECAN-DLNK Form and strength INJECTABLE;INJECTION - 100MG Sponsor DAIICHI SANKYO INC Submission history Latest submission status date: 2025-06-23 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.